Stock Ratings / Health Care / ALXO / insiders

DERM (31) MGNX (31) NGEN (49) CUE (33) ⌘ Pro Terminal →

ALX Oncology Holdings Inc. (ALXO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.22 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.22

ALX Oncology Holdings Inc. (ALXO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $152.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALXO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ALX Oncology Holdings Inc. (NASDAQ: ALXO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $1.22 (0.00% 1D, market cap $152.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ALXO ranks #296 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALXO compare to DERM and MGNX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALXO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DERM (Journey Medical Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M) and MGNX (MacroGenics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, ALXO leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALXO?

▼

Per ALXO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810182), ALX Oncology Holdings Inc. generated $0 in revenue, -$101.7M in net income, and -$84.4M in free cash flow against $59.0M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.22 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALXO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ALXO SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 47.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.25-15.2% Next Q

Q2 (-2Q)

Grade C$1.06+10.4% Next Q

Q3 (-1Q)

Grade C-$1.17+4.3% Next Q

Current

Grade D$1.22-1.4% Hist 90D α

Trajectory: C (58) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALXO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALXO currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.51) and Max Pain ($1.28) forces dealer call-delta covering toward $2.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALXO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALXO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ALXO Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ALXO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ALXO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALXO)

✓Walkthrough of ALXO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALXO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.24%▼ DESCENDING CHANNEL

2026-10-30O $1.20H $1.26L $1.20C $1.22VOL 421.0K

RES: $1.75SUP: $0.79SMA50: $1.51SMA200: $1.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALXO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALXO Butterfly Map → + Track ALXO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALXO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALXO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALXO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALXO)

Health Care Rank #296 of 1016 ⚔️ DERM vs ALXO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALXO vs. DERM, MGNX, NGEN, CUE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ALX Oncology Holdings Inc. (ALXO) ranks #296 by composite RQD confidence (50/100, grade D) and #607 by equity capitalization ($152.4M). Within this direct 5-issuer industry benchmark cohort, ALXO leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. ALXO currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALXO ACTIVE ALX Oncology Holdings Inc.	D	50/100	—	—	-35.0%	0.00%	$152.4M	Benchmark Subject
DERM Journey Medical Corporation	E	31/100	—	65.8%	-19.5%	-4.44%	$152.7M	/derm-vs-alxo →
MGNX MacroGenics Inc.	E	31/100	—	96.0%	-35.0%	+0.84%	$151.6M	/mgnx-vs-alxo →
NGEN NervGen Pharma Corp.	D	49/100	—	—	—	-4.86%	$155.0M	/ngen-vs-alxo →
CUE Cue Biopharma Inc.	E	33/100	—	—	-35.0%	-2.70%	$155.8M	/cue-vs-alxo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001810182

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ALX Oncology Holdings Inc. (ALXO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$101.7M, operating cash flow of -$84.1M, and free cash flow of -$84.4M (+31.1% YoY). On the balance sheet, ALXO closed FY2025 with $59.0M in total assets against $4.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$101.7M	-$84.1M	-$84.4M	$59.0M	$4.5M
FY2024 (FY)	2024-12-31	$0	-$134.8M	-$121.9M	-$122.4M	$147.8M	$9.5M
FY2023 (FY)	2023-12-31	$0	-$160.8M	-$130.4M	-$130.4M	—	—

3. ALXO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALXO compare to DERM and MGNX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALXO?

Where is ALXO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALXO last traded at $1.22 (0.00% on volume of 422,213 shares), positioning the stock -19.21% below its 50-day simple moving average ($1.51) and -32.97% below its 200-day simple moving average ($1.82). Across its 52-week range of $0.86 to $2.66, ALXO sits at the 20.0% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).

ALXO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ALXO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ALXO leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ALXO RQD Cockpit ALXO 12M Forecast ALXO Earnings & Move ALXO Dividends & DRIP ALXO Insiders & 13F ALXO Whale Options ALXO Profit Sankey ALXO News & Why

Sector Peer Dials

Compare →

DERM E

Journey Medical Corporation

Satellos Bioscience Inc.

58 /100

ALXO Core Snapshot

Market Cap $152.4M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $1.18

FREE TRADER TOOLS

Own ALXO Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With ALXO → 🏆 Trade ALXO in $100K Prop Arena →

ALXO Wire

Why It Moved →

Direct Company Event Moomoo • 6h ago

ALX Oncology(ALXO) Stock Options Chain | Quotes & News

Direct Company Event The Globe and Mail • 9h ago

Wells Fargo Remains a Buy on ALX Oncology Holdings (ALXO)

Peer / Ecosystem Wire TradingView • 12h ago

ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants With Key Holders

Peer / Ecosystem Wire Yahoo Finance Singapore • 15h ago

Coherus Oncology, Inc. (CHRS) stock price, news, quote and history

Peer / Ecosystem Wire Benzinga • 18h ago

12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALXO — ALX Oncology Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:42:31Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALXO scores 50 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC of -35%; FCF yield of 0%), Whale/13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 7/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12/20 (beta of 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z of 2.5; Piotroski F of 4/9; Debt/Equity of 0.17).

For a prospective investor, the weakest pillar is the cash engine: the rating reflects a return on invested capital of -35% and no free-cash-flow yield, meaning the business is consuming capital rather than generating it. The balance sheet pillar is the relative strength, with a Debt/Equity of 0.17 and an Altman Z of 2.5, but a Piotroski score of 4/9 signals only middling financial quality. Insider and institutional pillars sit in the lower-middle range, suggesting limited conviction signals in either direction. Upside, if it exists, would depend on a change in the cash-burn trajectory that the source data does not show; valuation cannot be assessed on earnings because no earnings multiples are available in the source data. This brief is educational and not personalized advice.

Business

Per the Profile section, ALX Oncology Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Products, customers, and revenue model are not described in the source data. Reported revenue across the financial periods provided is $0.0M in each year, consistent with a pre-revenue profile, but the source data does not describe the commercial pathway.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-104.0M	$-101.7M	N/A	$-84.4M	$16.4M	$4.5M
FY 2024	$0.0M	$-142.5M	$-134.8M	N/A	$-122.4M	$17.6M	$9.5M
FY 2023	$0.0M	$-170.3M	$-160.8M	N/A	$-130.4M	N/A	N/A

Per the SEC financials, operating losses narrowed from $-170.3M (FY 2023) to $-104.0M (FY 2025), and free-cash-flow burn declined from $-130.4M to $-84.4M over the same window. Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The per-the-Roarable-RQD forensic readings are an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.17. Cash of $16.4M in FY 2025 is small relative to the reported annual cash burn, a tension the source data does not resolve.

Recent Catalysts & News Wire Analysis

The news wire contains six items, all tagged to ALXO with a YELLOW signal light. Headlines reference a Wells Fargo "buy" commentary, an exchange of 13.35M shares for pre-funded warrants with key holders, a Q3'26 earnings entry showing a revenue estimate of 0 USD, and several market-movement and quote-page items. The share-exchange headline is the most substantive catalyst, as it concerns share-count and dilution mechanics; the source data does not provide the terms, pricing, or resulting share count. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded for the issuer.

Open Questions

What is the company's pipeline and revenue pathway, given $0.0M reported revenue across all periods?
What are the terms and resulting share count of the 13.35M-share pre-funded warrant exchange?
What is the cash runway, given FY 2025 cash of $16.4M against FY 2025 free-cash-flow burn of $-84.4M?
Why is FY 2023 cash and debt not reported in the source data?
What are the forward earnings or valuation expectations, given that no P/E or EV/EBITDA figures are available?

ALXO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ALX Oncology Holdings Inc. (ALXO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALXO Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 6h ago

ALX Oncology(ALXO) Stock Options Chain | Quotes & News

Moomoo report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 9h ago

Wells Fargo Remains a Buy on ALX Oncology Holdings (ALXO)

The Globe and Mail report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 12h ago

ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants With Key Holders

TradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 15h ago

Coherus Oncology, Inc. (CHRS) stock price, news, quote and history

Yahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18h ago

12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th

Benzinga report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

ALXO Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history

Yahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.dars.gov.et • 1d ago

ALX Oncology (ALXO) Rises 6% to $1.06 as Clinical-Stage Biotech Presses Toward Resistance - Key Reversal Day

www.dars.gov.et report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALXO Bull vs. Bear Conversation Board — What's Your Call at $1.22?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALXO 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.32 (+8.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALXO (D • RQD 50/100) a Buy at $1.22?

Welcome to the ALXO (ALX Oncology Holdings Inc.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.99 (-18.9%)

Spot @ $1.22

Pump the brakes on ALXO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALXO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ALX Oncology Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.43 (+17.2%)

Spot @ $1.22

ALXO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALXO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $0.86 - $2.66), any beat on forward guidance forces shorts and underweight funds to chase.